Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720. Fujiwara M, Anstadt EJ, Khanna KM, Clark RB Clin Immunol. 2015 Mar 28; 158(1):103-113. PMID: 25829233. Abstract CommentRecommendBookmarkWatch